Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Eyetech Macugen Filing Planned For Q3 In All Three AMD Subgroups

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Eyetech plans to submit its VEGF inhibitor Macugen in the third quarter for use in the three subtypes of wet age-related macular degeneration, the company noted in a prospectus for an initial public offering.

You may also be interested in...



Miravant Photrex Confirmatory Macular Degeneration Trial To Begin Mid-2005

 

Miravant Photrex Confirmatory Macular Degeneration Trial To Begin Mid-2005

 

Pfizer/Eyetech Macugen advisory committee

FDA's Dermatologic & Ophthalmic Drugs Advisory Committee will review Pfizer/Eyetech's Macugen (pegaptanib) for wet age-related macular degeneration Aug. 27. [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.] Completion of the rolling submission, under FDA's fast track provisions, is slated for the third quarter. Priority review was requested, Eyetech says. Pivotal data includes all three AMD subtypes; approval in each would give Macugen an edge over Novartis/QLT's Visudyne (verteporfin), indicated for predominantly classic subfoveal AMD (2Pharmaceutical Approvals Monthly Feb. 1, 2004, p. 6)...

Related Content

Topics

UsernamePublicRestriction

Register

PS002468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel